Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 136,942 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at $684,307,043.47. This represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.

Roivant Sciences Stock Up 3.1%

Shares of Roivant Sciences stock traded up $1.13 during midday trading on Tuesday, hitting $37.37. The company’s stock had a trading volume of 6,409,504 shares, compared to its average volume of 5,396,372. The firm has a market capitalization of $26.99 billion, a P/E ratio of -70.51 and a beta of 1.12. The stock has a 50-day simple moving average of $34.16 and a 200-day simple moving average of $30.17. Roivant Sciences Ltd. has a 1-year low of $11.54 and a 1-year high of $37.46.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently made changes to their positions in ROIV. Fifth Third Bancorp raised its stake in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after acquiring an additional 376 shares in the last quarter. Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Roivant Sciences by 4.6% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after purchasing an additional 445 shares in the last quarter. Versant Capital Management Inc grew its stake in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after acquiring an additional 487 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its stake in Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after purchasing an additional 500 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ROIV shares. HC Wainwright upped their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.